CAJ | 학술논문

目的：：探讨人重组白介素2联合顺铂治疗恶性胸腔积液的疗效和安全性。方法：60例恶性胸腔积液患者随机分为观察组(30例)和对照组(30例)。观察组排尽胸水后经胸腔内注入白介素2联合顺铂进行治疗；对照组排尽胸水后经胸腔内注入顺铂进行治疗。观察两组疗效与药品不良反应，比较两组患者生活质量和治疗前后免疫功能指标变化。结果：观察组有效率(83.3%)明显高于对照组(56.7%)，卡氏评分改善率(86.7%)也明显高于对照组(63.3%)，差异均有统计学意义(P<0.05)。治疗后，观察组CD4水平及CD4/CD8明显升高(P<0.05)，而对照组则明显降低(P<0.05)，两组比较差异有统计学意义(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论：白介素2联合顺铂治疗恶性胸腔积液疗效肯定。
목적：：탐토인중조백개소2연합순박치료악성흉강적액적료효화안전성。방법：60례악성흉강적액환자수궤분위관찰조(30례)화대조조(30례)。관찰조배진흉수후경흉강내주입백개소2연합순박진행치료；대조조배진흉수후경흉강내주입순박진행치료。관찰량조료효여약품불량반응，비교량조환자생활질량화치료전후면역공능지표변화。결과：관찰조유효솔(83.3%)명현고우대조조(56.7%)，잡씨평분개선솔(86.7%)야명현고우대조조(63.3%)，차이균유통계학의의(P<0.05)。치료후，관찰조CD4수평급CD4/CD8명현승고(P<0.05)，이대조조칙명현강저(P<0.05)，량조비교차이유통계학의의(P<0.05)。량조불량반응발생솔차이무통계학의의(P>0.05)。결론：백개소2연합순박치료악성흉강적액료효긍정。
Objective:To explore the curative effect and adverse reactions of cisplatin combined with rIL-2 on malignant pleural effusion. Methods:Totally 60 cases of patients with malignant pleural effusion were randomly divided into the observation group ( 30 cases) and the control group (30 cases). In the observation group, 30 cases were given intrapleural injection of cisplatin and rIL-2 af-ter the pleural effusions were drained, and in the control group, the patients received intrapleural injection of cisplatin. Both of the two groups were observed of tumor response and drug adverse reactions, compared the quelity of life and immune function indicators before and after treatment. Results:The response rate in the observation group was 83. 3%, which was significantly higher than that in the control group (56. 7%) (P<0. 05). The improvement of Karnofsky score in the observation group was 86. 7%, which was also nota-bly higher than that in the control group(63. 3%) (P<0. 05). After the treatment, CD4 level and CD4/CD8 were significantly in-creased in the observation group(P<0. 05), while those in the control group were notably decreased (P<0. 05), and the difference was statistically significant (P<0. 05). The incidence of adverse reactions shew no significant difference between the two groups (P>0. 05). Conclusion:Cisplatin combined with rIL-2 shows confirmed effects in the patients with malignant pleural effusion.